Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Metformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide. However, its use may be limited mainly by gastrointestinal adverse effects. Myo-inositol (MI), a well-recognized food supplement, also represents an evidence-based treatment for PCOS women, popular in many countries. Our aim is to provide a systematic review of the literature and a meta-analysis which compares these two treatments, for their short-term efficacy and safety in PCOS patients. Systematic review and meta-analysis of randomized clinical trials (RCTs). RCTs were identified from 1994 through 2017 using MEDLINE, Cochrane Library, PubMed, and ResearchGate. Included studies were limited to those one directly comparing MET to MI on several hormones changes. Standardized mean difference (SMD) or risk ratios (RRs) with 95% CIs were calculated. Changes in fasting insulin was the main outcome of measure. Six trials with a total of 355 patients were included. At the end of treatment, no difference between MET and MI was found on fasting insulin (SMD=0.08 µU/ml, 95% CI: -0.31-0.46, p=.697), HOMA index (SMD =0.17, 95% CI: -0.53-0.88, p=.635), testosterone (SMD= -0.01, 95% CI: -0.24-0.21, p=.922), SHBG levels (SMD= -0.50 nmol/l, 95% CI: -1.39-0.38, p=.263) and body mass index (BMI) (SMD= -0.22, 95% CI: -0.60-0.16, p=.265). There was strong evidence of an increased risk of adverse events among women receiving MET compared to those receiving MI (RR =5.17, 95% CI: 2.91-9.17, p<.001). No differences were found in the effect of MET and MI on short-term hormone changes. The better tolerability of MI makes it more acceptable for the recovery of androgenic and metabolic profile in PCOS women.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 2×
“The analysis of results was reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement [14].”
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“(Der Simonian–Laird method) [18] were used to obtain the”
MethodThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“(Mantel–Haenszel method) [17] and a random-effects model”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225 · cited 1×
“IR and reactive hyperinsulinemia are further stimulated by adipose tissue, being enhanced in obese patients [4].”
BackgroundPhosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287 · cited 1×
“At the molecular level, MET inhibits the mitochondrial respiratory chain in the liver, enhancing insulin sensitivity with effects on fat metabolism and reducing the expression of gluconeogenic enzymes [33].”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 2×
“Studies were included in the analysis if they met the following conditions: (a) designed as RCT; (b) use of MET versus MI; (c) population is represented by patients with PCOS diagnosed according Rotterdam Criteria [15] or Androgen Excess Society (AES) Guidelines [16]; (d) outcomes include at least one among the follow…”
Method
Research works printed but not linked: 2
- 10.1093/humrep/deh098 · DOI · Paper page
- Nehra J , Kaushal J , Singhal SR , et al. A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharm Sci Res. 2017;8:1664.
Cited by
Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome
Wang, J., Wu, D., Guo, H., & Li, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116940 · Cited by 322
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“in testosterone, androstenedione, and SHBG levels after inositol treatment compared to metformin [3, 56].”
BackgroundXing, C., Zhang, J., Zhao, H., & He, B. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s344542 · Cited by 118
“In addition, the superior tolerance to MI makes it suitable for the recovery of androgen and metabolic characteristics in women with PCOS.(105)”
BackgroundResultZhao, H., Xing, C., Zhang, J., & He, B. (2021) · Reproductive Health · doi:10.1186/s12978-021-01207-7 · Cited by 148
DiNicolantonio, J. J., & O’Keefe, J. H. (2022) · Open Heart · doi:10.1136/openhrt-2022-001989 · Cited by 134
Metadata
- Authors
- Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Lo.Li. Pharma S.r.l. (Italy) (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Facchinetti, Fabio
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2019-01-07
- Volume
- 35
- Issue
- 3
- Pages
- 198-206
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2910430746
- Cited by
- 94
- References
- 46
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 10 · 2023: 18 · 2022: 15 · 2021: 12 · 2020: 18 · 2019: 7
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- Gynecological Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, myo-inositol, polycystic ovary syndrome, insulin sensitizers, fasting insulin, HOMA index, testosterone, sex hormone-binding globulin, body mass index, adverse events, tolerability, metabolic profile, short-term treatment efficacy, women's health, dietary supplements, gastrointestinal adverse effects, insulin resistance, hyperandrogenism
- MeSH terms
- Female, Humans, Hypoglycemic Agents, Inositol, Metformin, Polycystic Ovary Syndrome, Randomized Controlled Trials as Topic, Treatment Outcome, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1080/09513590.2018.1540578
- The paper
- Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019). Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2018.1540578
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.